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Objectives: Neuropsychiatric symptoms and anosognosia are known to inﬂuence the perceived quality
of life of patients (QoL-p) with Alzheimer’s disease (AD). This study analysed their impact on patient
and caregiver ratings of QoL-p and how these ratings changed in relation to the severity of dementia.
Methods: A baseline sample of 221 patients and caregivers was followed up over 24months. Instru-
ments: Neuropsychiatric Inventory (NPI), Anosognosia Questionnaire—Dementia (AQ-D), Quality
of life—Alzheimer’s Disease (QoL-AD) and the Global Deterioration Scale (GDS). Longitudinal data
were analysed using generalized linear models.
Results: In the multivariate analysis, greater anosognosia was always associated with higher ratings of
QoL-p among patients, especially at 24months (p<0.001), and with more negative ratings among care-
givers, especially at baseline (p<0.001). A higher total NPI score was associated with a more negative
rating of QoL-p among caregivers (p<0.001), and it also had a smaller negative effect on patients’
self-ratings (p=0.001). The neuropsychiatric symptoms (NPI) associated with a more negative view
of QoL-p were depression, for patients’ self-ratings, and apathy and agitation for caregiver ratings.
The discrepancy between patient and caregiver ratings increased in line with the severity of dementia.
Conclusion: Neuropsychiatric symptoms had a similarly negative effect on the QoL-p ratings of both
patients and caregivers, whereas the effect of anosognosia differed according to the rater (positive for
patients, negative for caregivers). Copyright # 2015 John Wiley & Sons, Ltd.
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Introduction
Alzheimer’s disease (AD) is the most common subtype
of dementia, and its prevalence is predicted to increase
in years to come (Sosa-Ortiz et al., 2012). The conse-
quences it has for both patients and caregivers make
it a public health problem of considerable importance.
One of the symptoms that often accompany AD is
anosognosia, deﬁned as a lack of insight into one’s
own deﬁcits (Leicht et al., 2010). It is estimated that
anosognosia is present in as many as 80% of patients
with AD (Sevush and Leve, 1993), and it tends to
worsen as the dementia becomes more severe
(Kashiwa et al., 2005). Various factors have been linked
to anosognosia, including older age, less depression,
poorer functional ability (Conde-Sala et al., 2013) and
more behavioural and psychological symptoms of de-
mentia (BPSD) (Vogel et al., 2010; Spalletta et al., 2012).
BPSD are also in themselves one of the main symp-
toms of AD, with as many as 90% of patients present-
ing some symptoms of this kind (Fernández et al.,
2010). These symptoms have serious repercussions for
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patients and their surroundings, and they have a direct
impact on caregiver burden (Rymer et al., 2002).
Some studies have shown that patients with a greater
degree of anosognosia tend to hold a more positive
view of their own quality of life (Hurt et al., 2010).
Conversely, an increased presence of BPSD has been
related to more negative perceptions regarding the pa-
tient’s quality of life (QoL-p) among both patients
and caregivers (Ready et al., 2004; Hurt et al., 2008).
There is a need, however, to clarify the combined inﬂu-
ence that these two factors (anosognosia and BPSD)
have on patient and caregiver ratings of QoL-p.
Research has also identiﬁed discrepancies between
patient and caregiver ratings of QoL-p (Karlawish
et al., 2001; Ready et al., 2004; Zhao et al., 2012), with
caregivers having a less positive outlook regardingQoL-p.
In clinical practice, patients with anosognosia have
been observed to present more neuropsychiatric symp-
toms and dangerous behaviours, as well as greater
difﬁculties with treatment adherence (Starkstein et al.,
2007), leading to increased burden on caregivers
(Turró-Garriga et al., 2013). Studies have also shown
that these patients may have an overly positive view of
their own quality of life (Ready et al., 2006; Berwig
et al., 2009), an aspect that should be taken into account
when using quality-of-life measures to evaluate the effects
of therapeutic interventions. All these ﬁndings justify the
need to investigate the relationship between anosognosia,
neuropsychiatric symptoms and quality of life.
The general aim of this study was to obtain patient
and caregiver ratings of QoL-p and to analyse their
relationship to a series of clinical and socio-demogra-
phic factors over a 24-month period. Speciﬁcally, the
objectives were as follows: (1) To analyse the relation-
ship between anosognosia, neuropsychiatric symp-
toms, and patient and caregiver ratings of QoL-p;
and (2) to examine how these aspects change with
increasing severity of dementia. The study hypotheses
were that: (1) neuropsychiatric problems would be
more common among patients with anosognosia,
and (2) anosognosia and neuropsychiatric symptoms
would have a different inﬂuence on the QoL-p ratings
of patients and caregivers.
Methods
Design and study population
This was a longitudinal study involving a 24-month
follow-up of a consecutive sample of outpatients seen
at the Dementia Unit (Department of Neurology) of
Bellvitge University Hospital (Hospitalet de Llobregat,
Barcelona). They were all diagnosed as either AD ac-
cording to the criteria of the Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV, American Psy-
chiatric Association, 2001) or probable AD according
to the criteria of the National Institute of Neurological
and Communicative Disorders and Stroke/Alzheimer’s
Disease and Related Disorders Associations (NINCDS-
ADRDA; McKhann et al., 1984). In addition, they all
scored between 10 and 28 on the Mini-Mental State
Examination (MMSE; Folstein et al., 1975), thereby
enabling a quality-of-life scale (QoL-AD; Logsdon
et al., 2002) to be administered. The main caregiver
was deﬁned as the person with ongoing responsibility
for helping the patient with activities of daily living
(ADL). All the caregivers were relatives who received
no payment for the care they provided (i.e. informal
caregivers).
Patients were excluded if they presented vascular or
traumatic events, alcohol or substance dependency or
abuse, and if they had severe communication prob-
lems that prevented them from responding adequately
to the assessment instruments. Informed consent was
obtained for all participants. The study was approved
by the hospital’s Clinical Research Ethics Committee
(ref. PR162/10).
Instruments
Socio-demographic data for patients and caregivers
were gathered using a structured questionnaire
designed by the researchers.
• Quality of life. The Quality of Life—Alzheimer
Disease (QoL-AD) scale (Logsdon et al., 2002)
was used to assess the patient’s quality of life
(QoL-p) from the perspective of both patients and
caregivers. This instrument comprises 13 items that
refer to different aspects of the patient’s wellbeing.
Scores for each item range from 1 (poor) to 4
(excellent), yielding a total score between 13 and
52 (the higher the score the better the patient’s
quality of life).
• Behavioural and psychological symptoms of de-
mentia. This aspect was evaluated by means of the
Neuropsychiatric Inventory (NPI; Cummings
et al., 1994), which comprises 12 subscales that as-
sess the frequency and severity of 12 neuropsychiat-
ric symptoms (or BPSD), based on information
provided by caregivers. Scores range from 0 to
144, and the higher the score the greater the fre-
quency and severity of neuropsychiatric symptoms.
• Anosognosia. The Anosognosia Questionnaire—
Dementia (AQ-D; Migliorelli et al., 1995) was
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administered to patients and caregivers. It com-
prises 30 items referring to cognitive/functional
deﬁcits and changes in the patient’s behaviour, with
each item being rated according to the frequency of
occurrence, from 0 (never) to 3 (always). The total
score therefore ranges from 0 to 90. The degree of
anosognosia is estimated on the basis of the dif-
ference between patient and caregiver scores; the
greater the difference the greater the anosognosia.
The authors of the AQ-D consider that anosognosia
is present when this difference is ≥32.
• Cognitive assessment of the patient. This was based
on the Mini Mental State Examination (MMSE;
Folstein et al., 1975), a brief cognitive assessment
tool whose score ranges from 0 to 30 (the lower
the score the greater the cognitive deterioration).
The cut-off for cognitive impairment is 21/22.
Patients’ scores on the MMSE were corrected for
age and level of education (Blesa et al., 2001).
• Functional assessment of the patient. The Disability
Assessment for Dementia (DAD; Gélinas et al.,
1999) is a measure of basic and instrumental
ADL, and it was administered to the main care-
giver. The DAD comprises 40 items, and its total
score ranges from 40 to 80 (the higher the score
the greater the patient’s functional ability).
• Stage of dementia. This was based on the criteria of
the Global Deterioration Scale (GDS; Reisberg
et al., 1982), a tool designed to determine the stage
of a patient’s dementia. Patients were excluded if
they were classiﬁed as either GDS 7, because of
the severity of their dementia, or GDS 3, because
of the possible confusion with mild cognitive
impairment.
Procedure
Neurologists from the Dementia Unit selected eligible
patients according to the inclusion criteria and then
determined their stage of dementia using the GDS.
The sample was initially recruited between January
and December 2011, with the ﬁnal assessment at
24months being conducted in May 2014 The baseline
sample comprised 221 patients and their respective
caregivers, of whom 166 were able to be re-assessed
at 12months and 127 at 24months. Regarding the 94
(42.5%) patients lost to follow-up, 27 (28.7%) had
entered residential care, 31(32.9%) decided not to
participate any further, 2 (2.1%) had changed address
and 34 (36.1%) had died.
The aims of the study were explained to all partici-
pants in an introductory interview, and informed
consent was obtained from both patients and care-
givers before proceeding. Patients and their caregivers
were then interviewed separately by two clinical
psychologists trained in the administration of the re-
spective tests.
Calculation of sample size
Following previous studies (Portellano-Ortiz et al.,
2014) we calculated the sample size required to detect,
with a power of 80% and a conﬁdence level of 95%
based on the two-tailed Student’s t test for indepen-
dent samples, differences in the QoL-p variable
between patients and caregivers in two groups: No
anosognosia (≤32 AQ-D) and Anosognosia (>32
AQ-D). The programme used was Ene 3.0
(GlaxoSmithKline, UK).
QoL-p patients: with mean scores of 33.4 (SD=4.9)
in the No anosognosia group and 35.7 (SD=4.5) in
the Anosognosia group it would be necessary to in-
clude 59 subjects in the ﬁrst group and 81 in the
second.
QoL-p caregivers: with mean scores of 29.9
(SD=5.3) in the No anosognosia group and 23.9
(SD=4.4) in the Anosognosia group it would be
necessary to include 11 subjects in the ﬁrst group
and 15 in the second.
Statistical analysis
Longitudinal data were analysed by means of general-
ized linear models, because some dependent variables
were not normally distributed (Liang and Zeger,
1986; McCullagh and Nelder, 1989). This approach
enabled us to examine the general effects of the
independent variables on the response variable, with
respect to the factors time, patient group and the
interaction between the two (Time×Group), as well
as the simple effects of differences between the groups.
Two multivariate analyses were performed, taking
patient and caregiver ratings of QoL-p as the depen-
dent variables. The ﬁrst analysis used the overall scores
on the AQ-D and NPI, while the second analysis was
based on disaggregated scores from the NPI subscales.
Categorical variables were analysed by means of the
Pearson chi-square test. Cohen’s d was calculated as a
measure of effect size in relation to between group
differences in patient and caregiver ratings of QoL-p.
For hypothesis contrasts the level of statistical sig-
niﬁcance was set at .05. All data processing and
analysis were performed using SPSS v19.0 for
Windows (SPSS Inc., Chicago).
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Results
Sample description
The baseline sample comprised 221 patients and their
respective caregivers, of whom 166 completed the
follow-up assessment at 12months and 127 the assess-
ment at 24months. At baseline, lost cases (n=94)
were more impaired than were patients who com-
pleted the follow-up (n=127); speciﬁcally, they had
greater cognitive impairment (MMSE=17.2±5.5 vs.
19.1±5.2; z=2.4, p=0.014), poorer functional ability
(DAD=54.7±9.5 vs. 60.6±10.0; z=4.2, p<0.001), a
greater degree of anosognosia (AQ-D=38.9±18.2 vs.
30.2±18.2; t=3.4, p=0.001) and more neuropsychi-
atric symptoms (NPI=31.2±21.9 vs. 20.9±16.4;
z=3.9, p<0.001).
Sociodemographic and clinical data
The mean age of patients at baseline was 77.8 years
(SD=7.3). One hundred and forty of them (63.3%)
were women, and 140 (63.3%) had received fewer
than ﬁve years of formal schooling. The mean age of
caregivers at baseline was 63.8 years (SD=13.0). In
this case, 151 (68.3%) of them were women, and 56
(25.3%) had fewer than ﬁve years of formal education.
Across the follow-up period, patients showed a
deterioration in cognitive status (MMSE, p<0.001)
and functional ability (DAD, p<0.001). Patients’
scores on the NPI and AQ-D did not change signiﬁ-
cantly during follow-up.
Patient ratings of QoL-p did not change signiﬁ-
cantly over the follow-up period (p=0.443). Caregiver
ratings of QoL-p were always more negative than
those of patients, and had decreased further at
24months (p<0.001) (Figure 1a). The sociodemo-
graphic and clinical data for patients and caregivers
are presented in Table 1.
Anosognosia and neuropsychiatric symptoms
Model effects were analysed taking scores on the AQ-
D as the dependent variable and entering total and
subscale scores on the NPI as covariables. NPI scores
were positively associated with anosognosia (Wald
χ2=169.9, p<0.001), although the strength of associ-
ation decreased over time: baseline (Wald χ2=141.5,
p<0.001), 12months (Wald χ2=84.0, p<0.001) and
24months (Wald χ2=67.9, p<0.001).
Three NPI subscales, namely apathy (Wald χ2=
101.1, p<0.001), aberrant motor behaviour (Wald
χ2=41.3, p<0.001) and agitation (Wald χ2=33.2,
p<0.001) were directly associated with AQ-D scores
at all three assessment points. Depression (Wald χ2=
20.2, p<0.001) was always negatively associated with
anosognosia, although this relationship was only sig-
niﬁcant at the 12- and 24-month follow-ups.
The group of patients with anosognosia had more
neuropsychiatric symptoms at all three assessment
points (p<0.001) (Table 2).
Neuropsychiatric symptoms, anosognosia and quality of
life
Comparison of patients with high and low levels of
BPSD showed that the latter always gave higher
ratings of QoL-p, although the difference was only
signiﬁcant in the assessment at 24months. By contrast,
higher levels of BPSD were always associated with
a. Scores of patients and b. Effect of BPSD on c. Effect of anosognosia on
caregivers on the QoL-p QoL-p ratings  QoL-p ratings
Figure 1 Quality of life of patients, in patients and caregivers. Effects of neuropsychiatric symptoms and anosognosia.
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signiﬁcantly lower caregiver ratings of QoL-p
(p<0.001) (Figure 1b). Comparison of patients with
and without anosognosia revealed that the former pre-
sented more neuropsychiatric symptoms and gave
higher ratings of QoL-p; conversely, caregiver ratings
of QoL-p were lower for the group of patients with
anosognosia (Figure 1c). These differences increased
over time (Table 2).
It can be seen in Table 3 that patients own ratings of
their QoL were higher in the presence of anosognosia
(regardless of the degree of neuropsychiatric symp-
toms). Conversely, higher caregiver ratings of QoL-p
were associated with fewer neuropsychiatric symptoms
(with or without anosognosia). It should also be noted
that anosognosia had an opposite effect on the QoL-p
ratings of patients (positive) and caregivers (negative),
whereas neuropsychiatric symptoms had a similar effect
on both sets of ratings, albeit to a different extent.
Severity of dementia and quality of life
Both anosognosia (p<0.001) and neuropsychiatric
symptoms (p<0.001) increased signiﬁcantly in line with
increasing severity of dementia, although there were no
signiﬁcant differences between the three assessment
points, with the exception of patients classiﬁed as GDS
6, who presented less anosognosia at 24months.
Patient ratings of QoL-p did not differ signiﬁcantly as
a function of the severity of dementia in any of the three
assessments. By contrast, caregiver ratings of QoL-p
decreased signiﬁcantly in line with increasing severity
of dementia (p<0.001) at all three assessment points.
The discrepancy between patient and caregiver
ratings of QoL-p increased in line with the severity
of the dementia (Table 4).
Multivariate analysis: effect of anosognosia and neuro-
psychiatric symptoms on ratings of QoL-p
Total scores: In patients, greater anosognosia was associ-
ated with higher ratings of QoL-p, most notably at
24months (p<0.001). Neuropsychiatric symptoms had
less of an effect on patients’ self-ratings of QoL. Greater
anosognosia in the patient had a negative effect on care-
giver ratings of QoL-p at all three assessment points,
most notably at baseline. Neuropsychiatric symptoms
had a stronger effect than did anosognosia on caregiver
ratings of QoL-p at all three assessment points, although
in this case the effect was strongest at 24months.
NPI scores by subscale: Depression was the factor
that had the strongest negative effect on patients’
self-ratings of QoL. Conversely, apathy and agitation
in the patient were the factors that most negatively
Table 1 Sociodemographic and clinical data of patients and caregivers
Baseline 12months 24months Differences
1 (n = 221) 2 (n = 166) 3 (n = 127) Test df p
Patient factors
Women, n (%) 140 (63.3) 104 (62.7) 82 (64.6) 0.1 2 0.944 1
School (<5 years), n (%) 140 (63.3) 108 (65.1) 84 (66.1) 0.2 2 0.861 1
Age, mean (SE) 77.8 (0.4) 78.6 (0.5) 79.0 (0.6) 2.5 2 0.276 2
MMSE, mean (SE) 18.3 (0.3) 16.3 (0.4) a 15.8 (0.6) b 17.0 2 <0.001 2
DAD, mean (SE) 58.1 (0.6) 54.0 (0.7) a 50.0 (0.8) b, c 55.7 2 <0.001 2
NPI, mean (SE) 25.3 (1.2) 24.4 (1.4) 28.6 (1.6) 4.3 2 0.116 2
AQ-D, mean (SE) 33.9 (1.2) 34.3 (1.5) 36.2 (2.0) 1.1 2 0.603 2
Caregiver factors
Women, n (%) 151 (68.3) 107 (64.5) 81 (63.8) 0.9 2 0.611 1
School (<5 years), n (%) 56 (25.3) 42 (25.3) 30 (23.6) 0.1 2 0.929 1
Age, mean (SE) 63.8 (0.8) 65.7 (0.9) 65.7 (1.1) 2.9 2 0.226 2
Quality of Life (QoL-AD)
Patients, mean (SE) 35.1 (0.3) 35.4 (0.4) 35.9 (0.5) 1.6 2 0.443 2
Caregivers, mean (SE) 27.3 (0.3) 26.2 (0.4) a 25.0 (0.4) b 15.5 2 <0.001 2
Simple effects. χ2 (df) p 246.5 (1)<0.001 235.8 (1)<0.001 218.9 (1)<0.001
• Model. χ2 (df) p Time = 2.7 (2) 0.254; Groups = 678.1 (1)< 0.001; Time ×Groups = 12.7 (2) 0.002
1Pearson χ2 test. p-values < 0.05 are shown in bold.
2Generalized linear model Wald χ2; means, estimated marginal; SE, standard error; signiﬁcant with Bonferroni post hoc contrasts:
a1–2,
b1–3,
c2–3.
MMSE, Mini Mental State Examination; DAD, Disability Assessment for Dementia; NPI, Neuropsychiatric Inventory; AQ-D, Anosognosia Ques-
tionnaire—Dementia; QoL-AD, Quality of Life—Alzheimer’s Disease; QoL-p, Quality of life of patient.
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inﬂuenced caregiver ratings of QoL-p at all three as-
sessment points. The negative effect of depression on
patient ratings and of apathy and agitation on care-
giver ratings increased over time (Table 5).
Discussion
Quality of life of the patient, anosognosia and neuro-
psychiatric symptoms
The ﬁrst aim of this study was to analyse the relation-
ship between anosognosia (AQ-D), neuropsychiatric
symptoms (NPI) and the quality of life of patients with
AD (QoL-AD). The results showed that patients with
anosognosia presented more BPSD and gave higher
ratings of their own QoL. In contrast to what occurred
with patients, caregiver ratings of QoL-p were more
negative in the case of patients with anosognosia. This
illustrates the way in which subjective and proxy ratings
of quality of life may differ. While some authors have
cast doubt on the reliability of QoL ratings of patients
with high levels of anosognosia (Vogel et al., 2006;
Berwig et al., 2009), others have argued that the two
perspectives (patients vs. caregivers) can be regarded
as equally valid and as highlighting different aspects
(Logsdon et al., 2002; Ready et al., 2006; Trigg et al.,
2011). From a clinical perspective, therefore, different
criteria should also be applied when interpreting the
ratings of patients and their caregivers.
Table 2 Differences in QoL between the groups deﬁned in relation to AQ-D and NPI
1. Baseline 2. 12months 3. 24months Simple effects
n Mean (SE) n Mean (SE) n Mean (SE) χ2 df p
NPI and AQ-D groups
No anosognosia 101 14.4 (1.6) 55 16.2 (2.1) 31 17.2 (2.9) 0.9 2 0.627
Anosognosia 120 34.5 (1.4) 111 28.4 (1.5) a 96 32.3 (1.6) 8.1 2 0.017
Simple effects. χ2 (df) p 83.7 (1)<0.001 20.5 (1)<0.001 20.1 (1)<0.001
• Model. χ2 (df) p Time = 1.8 (2) 0.392; Groups = 96.2 (1)< 0.001; Time ×Groups = 5.4 (2) 0.065
QoL and BPSD groups
QoL-p patient
Low BPSD 121 35.1 (0.4) 90 36.0 (0.5) 58 36.9 (0.7) 5.2 2 0.071
High BPSD 100 35.1 (0.4) 76 34.7 (0.6) 69 34.7 (0.7) 0.3 2 0.856
Simple effects χ2 (df) p 0.0(1) 0.963 2.4 (1) 0.118 4.6 (1) 0.032
• Model. χ2 (df) p Time = 1.3 (2) 0.505; Groups = 5.8 (1) 0.016; Time ×Groups = 3.7 (2) 0.156
QoL-p caregiver
Low BPSD 121 29.9 (0.4) 90 28.3 (0.5) 58 28.0 (0.6) b 8.7 2 0.003
High BPSD 100 24.1 (0.4) 76 23.7 (0.5) 69 22.6 (0.5) 4.1 2 0.123
Simple effects χ2 (df) p 77.9 (1)<0.001 38.1 (1)<0.001 38.5 (1)<0.001
• Model. χ2 (df) p Time = 11.1 (2) 0.004; Groups = 143.1 (1)< 0.001; Time ×Groups = 1.1 (2) 0.532
QoL and AQ-D groups
QoL-p patient
No anosognosia 101 34.1 (0.4) 55 33.3 (0.6) 31 33.7 (0.8) 1.1 2 0.570
Anosognosia 120 35.9 (0.4) 111 36.9 (0.5) 96 37.2 (0.6) 4.2 2 0.122
Simple effects χ2 (df) p 7.7 (1) 0.006 19.5 (1)<0.001 11.4 (1)<0.001
• Model. χ2 (df) p Time = 0.5 (2) 0.748; Groups = 36.5 (1)< 0.001; Time ×Groups = 4.2 (2) 0.121
QoL-p caregiver
No anosognosia 101 30.4 (0.4) 55 29.1 (0.6) 31 29.8 (0.8) 2.3 2 0.315
Anosognosia 120 24.7 (0.4) 111 24.8 (0.4) 96 23.5 (0.5) 4.3 2 0.114
Simple effects χ2 (df) p 73.4 (1)<0.001 29.4 (1)<0.001 39.1 (1)<0.001
• Model. χ2 (df) p Time = 2.6 (2) 0.271; Groups = 126.9 (1)< 0.001; Time ×Groups = 2.6 (2) 0.272
Generalized linear model, Wald χ2, for time, groups and interaction; simple effects, Wald χ2 for differences between groups; means, estimated mar-
ginal; SE, standard error; p-values < 0.05 are shown in bold. Signiﬁcant with Bonferroni post hoc contrasts:
a1–2,
b1–3,
c2–3.
NPI, Neuropsychiatric Inventory; AQ-D, Anosognosia Questionnaire—Dementia; QoL-AD, Quality of Life—Alzheimer’s Disease; QoL-p, Qual-
ity of life of patient; BPSD, Behavioural and Psychological Symptoms of Dementia.
Groups: No anosognosia (<32 AQ-D); Anosognosia (≥32 AQ-D); low BPSD (<25 NPI); high BPSD (≥25 NPI). In the NPI groups the mean score
was used as the reference.
J. L. Conde-Sala et al.
Copyright # 2015 John Wiley & Sons, Ltd. Int J Geriatr Psychiatry 2015
Although the strong association between anosog-
nosia and BPSD is consistent with previous ﬁndings
(Kashiwa et al., 2005; Starkstein et al., 2007), these
two variables did not have the same effect on pa-
tients’ ratings of their own QoL: greater anosognosia
was associated with higher ratings, whereas ratings
became more negative in the presence of more neuro-
psychiatric symptoms. This suggests that these vari-
ables have an independent and opposing effect on
patients. Among caregivers, the presence of greater
anosognosia (Tatsumi et al., 2009; Conde-Sala et al.,
2014a) and of more neuropsychiatric symptoms
(Karttunen et al., 2011; Tay et al., 2014) always had
the same negative effect on their ratings of QoL-p.
Quality of life and severity of dementia
The second aim of this study was to analyse how
anosognosia, neuropsychiatric symptoms, and patient
and caregiver ratings of QoL-p change with increasing
severity of dementia. In line with previous studies,
both anosognosia (Kashiwa et al., 2005; Starkstein
et al., 2006) and the number of BPSD (Zuidema
et al., 2009; Robles Castiñeiras et al., 2012) increased
as the dementia becamemore severe (higher GDS stage).
This increase could be because of neurological deteriora-
tion, and speciﬁcally to frontal lobe alterations, which
would be exacerbated with increasing disease severity
(Vogel et al., 2005; Spalletta et al., 2012).
Regarding QoL-p, the perception of caregivers was
signiﬁcantly more negative as the dementia became
more severe, although patients’ own ratings did not alter
signiﬁcantly (Trigg et al., 2015). This more negative view
among caregivers would be related to the severity of the
dementia and the distress they experience when having
to deal with a greater number of BPSD (Karlawish
et al., 2001; Cheng et al., 2013) and increased functional
impairment in the patient (Conde-Sala et al., 2014b).
The lower ratings of QoL-p obtained from patients
without anosognosia (in the early stages of dementia)
could be related to psychological factors, as these indi-
viduals are likely to be more depressed by the aware-
ness of their own deﬁcits (Sevush and Leve, 1993;
Conde-Sala et al., 2014a). A recent 12-month follow-
up study (Portellano-Ortiz et al., 2014) that assessed
depression directly using the Geriatric Depression
Scale likewise found that it was associated with less
anosognosia, although the observed association was
Table 3 Differences in QoL-p between groups, combining scores from the AQ-D and NPI
Baseline 12months 24months Simple effects
n Mean (SE) n Mean (SE) n Mean (SE) χ2 df p
QoL-p patient
1. Anosog/low NPI 41 36.2 (0.7) 49 36.8 (0.6) 31 37.4 (0.8) 0.5 2 0.763
2. Anosog/high NPI 79 35.7 (0.5) 57 35.7 (0.6) 53 36.2 (0.6) 1.1 2 0.561
3. No-anosog/low NPI 80 34.5 (0.5) 41 34.3 (0.7) 27 34.4 (0.8) 1.9 2 0.379
4. No-anosog/high NPI 21 32.8 (0.9) c 19 31.1 (1.0) c,e 16 31.0 (1.1) c,e 0.0 2 0.979
Simple effects. χ2 (df) p 10.5 (3) 0.014 23.8 (3)<0.001 24.0 (3)<0.001
• Model. χ2 (df) p Time = 0.3 (2) 0.828; Groups = 56.5 (3)< 0.001; Time ×Groups = 3.2 (6) 0.775
QoL-p caregiver
1. Low NPI/no-anosog 80 31.3 (0.5) 41 30.4 (0.7) 27 29.7 (0.8) 2.7 2 0.248
2. Low NPI/anosog 41 27.3 (0.7) a 49 26.6 (0.6) a 31 26.4 (0.8) a 0.6 2 0.721
3. High NPI/no-anosog 21 26.9 (1.0) b 19 24.8 (1.0) b 16 24.8 (1.1) b 2.4 2 0.292
4. High NPI/anosog 79 23.4 (0.5) c,e,f 57 23.3 (0.6) c,e 53 21.9 (0.6) c,e 4.0 2 0.132
Simple effects. χ2 (df) p 117.9 (3)<0.001 59.3 (3)<0.001 56.1 (3)<0.001
• Model. χ2 (df) p Time = 7.0 (2) 0.029; Groups = 205.2 (3)< 0.001; Time ×Groups = 2.1 (6) 0.910
Generalized linear model, Wald χ2, for time, groups and interaction; simple effects, Wald χ2 for differences between groups; means, estimated mar-
ginal; SE, standard error; p-values < 0.05 are shown in bold. Signiﬁcant with Bonferroni post hoc contrasts:
a1–2,
b1–3,
c1–4,
d2–3,
e2–4,
f3–4.
NPI, Neuropsychiatric Inventory; AQ-D, Anosognosia Questionnaire—Dementia; QoL-AD, Quality of Life—Alzheimer’s Disease; QoL-p,
Quality of life of patient.
Groups: No anosognosia (<32 AQ-D); Anosognosia (≥32 AQ-D); low NPI (<25); high NPI (≥25). In the NPI groups the mean score was used as
the reference.
Anosognosia and neuropsychiatric symptoms in AD
Copyright # 2015 John Wiley & Sons, Ltd. Int J Geriatr Psychiatry 2015
not as strong as when depression was evaluated by
caregivers using the NPI.
Conversely, the greater anosognosia and higher
ratings of QoL-p observed in more advanced stages
of dementia could be related to the biological factors
that are implicit to increased neurological impairment
(Sedaghat et al., 2010; Spalletta et al., 2012).
Limitations and future directions
Although it is a common problem in follow-up studies
the loss of cases between the two assessment points
could have inﬂuenced some of the results. For
instance, if the lost cases had had higher baseline
scores for anosognosia and neuropsychiatric symp-
toms, the trend would be similar to that observed in
the followed-up cases, although QoL-AD scores would
have been even more different between the subgroups.
A further limitation of the study is that certain care-
giver factors which may inﬂuence the evaluation of
anosognosia and quality of life, namely gender, burden
and depression, were not analysed in sufﬁcient detail.
Future studies should focus on the analysis of
anosognosia in the early stages of dementia and of
the factors associated with it, because the majority
of patients with more severe dementia will be affected
by anosognosia.
Table 4 Severity of dementia: anosognosia, behaviour and quality of life
Baseline 12months 24months Simple effects
n Mean (SE) n Mean (SE) n Mean (SE) χ2 df p
AQ-D (Anosognosia)
GDS 4 97 22.5 (1.5) 38 20.8 (2.4) 12 16.4 (4.3) 1.8 2 0.390
GDS 5 78 38.4 (1.5) a 67 35.1 (1.8) a 40 38.3 (2.4) a 1.9 2 0.375
GDS 6 46 50.3 (2.2) b,c 61 48.4 (2.6) b,c 75 41.1 (2.6) c,d 7.5 2 0.023
Simple effects. χ2 (df) p 116 (2)<0.001 58.2 (2)<0.001 24.8 (2)<0.001
• Model. χ2 (df) p Time = 6.0 (2) 0.048; GDS = 139.1 (2) <0.001; Time ×GDS= 5.9 (4) 0.206
NPI (behaviour)
GDS 4 97 16.9 (1.6) 38 15.0 (2.6) 12 11.6 (4.7) 1.2 2 0.529
GDS 5 78 28.2 (1.8) a 67 23.5 (2.0) a 40 24.4 (2.6) 3.1 2 0.209
GDS 6 46 38.0 (2.4) b,c 61 31.2 (2.1) b,c 75 33.6 (1.9) b,c 4.5 2 0.103
Simple effects. χ2 (df) p 54.2 (2)<0.001 22.6 (2)<0.001 21.8 (2)<0.001
• Model. χ2 (df) p Time = 7.8 (2) 0.020; GDS = 77.7 (2) <0.001; Time ×GDS= 1.4 (4) 0.835
QoL-p patient
GDS 4 97 35.6 (0.4) 38 35.4 (0.7) 12 35.1 (1.3) 0.1 2 0.933
GDS 5 78 35.1 (0.5) 67 35.4 (0.5) 40 36.7 (0.7) 3.2 2 0.194
GDS 6 46 34.0 (0.7) 61 35.5 (0.8) 75 35.2 (0.8) 2.3 2 0.315
Simple effects. χ2 (df) p 3.4 (2) 0.178 0.0 (2) 0.991 2.1 (2) 0.337
• Model. χ2 (df) p Time = 1.9 (2) 0.380; GDS= 1.9 (2) 0.371; Time ×GDS= 3.0 (4) 0.550
QoL-p caregiver
GDS 4 97 30.3 (0.4) 38 31.0 (0.7) 12 32.4 (1.3) 2.3 2 0.305
GDS 5 78 26.1 (0.5) a 67 26.5 (0.5) a 40 27.4 (0.7) a 2.0 2 0.361
GDS 6 46 23.0 (0.5) b,c 61 23.0 (0.5) b,c 75 22.6 (0.5) b,c 0.2 2 0.863
Simple effects. χ2 (df) p 84.0 (2)<0.001 69.7 (2)<0.001 60.3 (2)<0.001
• Model. χ2 (df) p Time = 2.4 (2) 0.299; GDS= 176.3 (2) <0.001; Time ×GDS= 3.2 (4) 0.523
Discrepancy QoL-p patients–caregivers
GDS 4 97 5.3 (0.5) 38 4.4 (0.9) 12 2.7 (1.6) 2.4 2 0.289
GDS 5 78 8.9 (0.6) a 67 8.8 (0.7) a 40 9.1 (0.9) a 0.0 2 0.972
GDS 6 46 10.9 (0.8) b 61 11.9 (0.9) b,c 75 10.6 (0.9) b 1.0 2 0.592
Simple effects. χ2 (df) p 36.6 (2)<0.001 32.3 (2)<0.001 17.2 (2)<0.001
• Model. χ2 (df) p Time = 1.4 (2) 0.492; GDS= 69.7 (2) <0.001; Time ×GDS= 2.8 (4) 0.583
Generalized linear model, Wald χ2, for time, groups and interaction; simple effects, Wald χ2 for differences between groups; means, estimated mar-
ginal; SE, standard error; p-values < 0.05 are shown in bold. Signiﬁcant with Bonferroni post hoc contrasts:
aGDS 4–5,
bGDS 4–6,
cGDS 5–6,
dbaseline–24months.
NPI, Neuropsychiatric Inventory; AQ-D, Anosognosia Questionnaire—Dementia; QoL-AD, Quality of Life—Alzheimer’s Disease; QoL-p, Qual-
ity of life of patient; GDS, Global Deterioration Scale.
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Conclusions
Anosognosia and neuropsychiatric symptoms both
increased in line with the severity of dementia,
although they had differential effects on patient and
caregiver ratings of QoL-p. Patients gave more positive
ratings of their own QoL in the presence of greater
anosognosia and fewer neuropsychiatric symptoms.
Among caregivers, greater anosognosia and more
neuropsychiatric symptoms were always associated
with more negative ratings of QoL-p.
Caregivers’ views of QoL-p became signiﬁcantly
more negative in line with the severity of dementia
(GDS stage), whereas no such change was observed
among patients. Caregiver ratings of QoL-p were
always more negative than those of patients.
Clinical implications
BPSD are common among patients with AD, and
they have a signiﬁcant impact on caregivers.
Consequently, there is a need for interventions
that can help caregivers develop coping strategies
for dealing with these symptoms (García-Alberca
et al., 2013).
When assessing the quality of life of patients with
dementia it is important to take into account those
factors which may inﬂuence patients’ own ratings
depending on the stage of their illness, with depres-
sion and anosognosia being especially relevant in this
regard. It would seem advisable, therefore, for greater
attention to be paid to the assessment of anosognosia,
using speciﬁc brief instruments (Turró-Garriga et al.,
2014).
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Key points
• During the 24-month follow-up, patients’ self-
appraisals of quality of life remained stable,
whereas the corresponding views of caregivers
became more negative.
• In patients, greater anosognosia and, to a lesser
extent, fewer neuropsychiatric symptoms were
associated with more positive ratings of their
quality of life.
• Among caregivers, neuropsychiatric symptoms
and, to a lesser extent, anosognosia in the patient
were associated with more negative ratings of the
patient’s quality of life.
• The neuropsychiatric symptoms (NPI) associated
with a more negative view of the patient’s quality
of life were depression, for patients’ self-ratings,
and apathy and agitation for caregiver ratings.
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